Histogen Inc. financial data

Location
10655 Sorrento Valley Road, Suite 200, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Conatus Pharmaceuticals Inc. (to 5/21/2020), Conatus Pharmaceuticals Inc (to 6/23/2014)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 773 % -24%
Debt-to-equity 44.7 % +28.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.27M shares 0%
Common Stock, Shares, Outstanding 4.27M shares 0%
Entity Public Float 5.4M USD -87.4%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 4.27M shares +20.2%
Weighted Average Number of Shares Outstanding, Diluted 4.27M shares +20.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 19K USD -99.5%
Research and Development Expense 3.28M USD -40.8%
General and Administrative Expense 8.8M USD -2.71%
Operating Income (Loss) -12.1M USD -11.5%
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -2.83 USD/shares +10.9%
Earnings Per Share, Diluted -2.83 USD/shares +10.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.57M USD -68.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 40K USD -57%
Assets, Current 5.46M USD -66.6%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 4.49M USD -6.73%
Other Assets, Noncurrent 362K USD -43.3%
Assets 5.82M USD -73.8%
Accounts Payable, Current 386K USD -31.2%
Employee-related Liabilities, Current 787K USD +443%
Accrued Liabilities, Current 943K USD +59%
Liabilities, Current 1.35M USD -3.58%
Operating Lease, Liability, Noncurrent 4.24M USD -5.88%
Liabilities 1.41M USD -76.2%
Retained Earnings (Accumulated Deficit) -97.7M USD -14.5%
Stockholders' Equity Attributable to Parent 5.44M USD -68.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 4.4M USD -72.9%
Liabilities and Equity 5.82M USD -73.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.55M USD -639%
Net Cash Provided by (Used in) Financing Activities -2K USD +99.6%
Net Cash Provided by (Used in) Investing Activities -15K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 4.27M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.55M USD -205%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.87M USD -67.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD -75%
Deferred Tax Assets, Valuation Allowance 24.7M USD +7.98%
Deferred Tax Assets, Gross 25.7M USD +6.67%
Operating Lease, Liability 4.5M USD -4.5%
Payments to Acquire Property, Plant, and Equipment 15K USD
Lessee, Operating Lease, Liability, to be Paid 7.21M USD -9.63%
Property, Plant and Equipment, Gross 1.2M USD -0.41%
Operating Lease, Liability, Current 265K USD +25%
Lessee, Operating Lease, Liability, to be Paid, Year Two 827K USD +2.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 803K USD +2.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.7M USD -17.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 853K USD +3.14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 816K USD +19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 879K USD +3.05%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 978K USD -18.4%
Share-based Payment Arrangement, Expense 534K USD +18.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%